Strong Buy with 3.45% yield, 8% EPS growth outlook, and 12.6–16.4% CAGR potential. Read the full analysis here.

Lyme disease is less of a worry in late summer, according to URI's top tick researcher. But the risk of alpha-gal syndrome ...

As hotter summers become the norm, home aircon can feel increasingly tempting. We put six units to the test for cooling power, noise and energy use – and explain what you need to know before buying ...

Every AI-driven capability available to cyber security providers is also available, or adaptable, to cyber attackers, says.

The goal should not be to ensure that every rural household has enough food in terms of calories, but the food available is ...

The headline numbers are striking: Writer says its agent product now operates at an average 52% lower cost, with a 48% improvement in speed and a 10% improvement in quality when paired with Palmyra X6 ...

JavaScript Explicit Resource Management lands in Safari Technology Preview 250, completing cross-browser support across V8, ...

Over a decade ago, scientists redefined how to study organ development by generating seemingly unremarkable clumps of cells. They dubbed them organoids: organ-like microstructures produced using stem ...

Walk into any casino and you will still find rows of three-reel machines with cherries, bars and sevens on them. They have survived every trend the industry has thrown at them from video reels and ...

Keeping $30,000 in a low-yield big-bank savings account can cost about $1,194 a year in 2026. See what cash to keep close and what could earn more instead.

Corvus Pharmaceuticals is rated Hold, with valuation driven almost entirely by the success of its lead asset, soquelitinib.